Boehringer Ingelheim and BioMed X have entered a collaboration to establish a research group focused on identifying novel therapeutic concepts for treating chronic obstructive pulmonary disease (COPD). Further details and financial terms were not disclosed.   The companies will jointly select the best ideas and life science talents to form a new research group within BioMed X’s open innovation lab in Heidelberg. BioMed X has developed an innovation model offering a project plan, funding pa...